![]() |
HIV-Related Drug Classes Navigation |
||
| Anti-HIV Drug Classes (Home) | ||
Enfuvirtide (Fuzeon ®) |
||||||||
|
Fusion protein inhibitor. Dosing (Adults): 90 mg SQ twice daily. (Administer subcutaneously into upper arm, abdomen, or anterior thigh.) Supplied: Injection (powder for reconstitution): 108 mg (90 mg/ml following reconstitution). |
||||||||
maraviroc (Selzentry™) |
||||||||
|
INDICATIONS AND USAGE: SELZENTRY™ is a CCR5 co-receptor antagonist indicated for combination
antiretroviral treatment of adults infected with only CCR5-tropic HIV-1detectable, who have evidence of viral replication and HIV-1 strains
resistant to multiple antiretroviral agents. Tropism and treatment
history should guide the use of SELZENTRY. MOA: selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120. Blocking this interaction prevents CCR5-tropic HIV-1 entry into cells. Recommended Dosing Regimen
Supplied: Tablets: 150 mg and 300 mg |
||||||||
raltegravir (Isentress ®) |
||||||||
|
INDICATIONS AND USAGE: ISENTRESS™ is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated: • In combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents . The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients Dosing (Adults): 400 mg administered orally, twice daily with or without food Supplied: Tablets: 400 mg |
||||||||
Disclaimer
|
||||||||
|
Listed dosages are for - Adult patients ONLY. PLEASE READ THE
DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
GlobalRPH does not directly or indirectly practice medicine or provide
medical services and therefore assumes no liability whatsoever of any
kind for the information and data accessed through the Service or for
any diagnosis or treatment made in reliance thereon. David F. McAuley, Pharm.D., R.Ph. GlobalRPh Inc. |
| Disclaimer Contact Us Privacy Policy Website Search | We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc. |
![]() |
|
